News Articles

Takeda Continues Ongoing Inclusion in the FTSE4Good Developed Index & MSCI ESG Leaders Index OSAKA, Japan -Thursday 11 July 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been selected for the 15th consecutive year by the FTSE4Good Developed Index, one of the world’s premier indices for Socially Responsible Investment (SRI), created by...

Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized... -Monday 8 July 2019

- Updated results from the Phase IIIb/IV PROPEL Study show that pharmacokinetic (PK)-driven dosing may be used to achieve FVIII target trough levels of 8–12%; and that selecting a patient-appropriate target FVIII level plus adjusting a dosing regimen to that patient’s PK characteristics,...

Takeda to Demonstrate Global Leadership in Hematology at ISTH 2019 -Wednesday 3 July 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress...

Takeda Completes Sale of Xiidra® to Novartis -Monday 1 July 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential...

Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease... -Friday 28 June 2019

Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community. Through its annual Global CSR Program,...

Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis -Sunday 9 June 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis did not meet the first of two primary endpoints. Treatment with...

Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on... -Friday 7 June 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that new data for TAK-788 will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 3 at 10:12 a.m. CT in Chicago. Results from a...

Takeda Makes First Private Sector Pledge for Global Fund Replenishment -Tuesday 4 June 2019  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today became the first private sector company to announce a financial commitment to the Global Fund’s Sixth Replenishment. The new pledge, consisting of JP ¥ 1 billion over five years, builds on...

New Ad-hoc Analysis of Phase 3 HELP Study™ Evaluates Prevention of HAE Attacks with... -Monday 3 June 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from an ad-hoc analysis of the Phase 3 HELP Study™, designed to evaluate the onset of action for TAKHZYRO® (lanadelumab) during days 0-69 of treatment. The analysis suggests...

Takeda to Showcase Growing Pipeline and Diversified Portfolio of Oncology Products at Upcoming Scientific Congresses -Monday 20 May 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24th Congress of the European Hematology...

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority... -Monday 20 May 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha...

Takeda and London School of Hygiene & Tropical Medicine Establish "Takeda Chair in Global Child Health" -Saturday 18 May 2019  

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of the Takeda Chair in...

Takeda Reports FY2018 Full Year Results and Issues FY2019 Guidance -Thursday 16 May 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): FY2018 Full Year Results Legacy Takeda Underlying Revenue +5.3%; Consolidated reported revenue +18.5% Underlying Revenue growth for Legacy Takeda was solid at +5.3%, with significant contributions from...

Takeda to Highlight New Research into the Long-term Complications of Chronic Hypoparathyroidism at the European Congress... -Wednesday 15 May 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will feature 7 presentations, including one oral presentation, at the upcoming European Congress of Endocrinology (ECE) Annual Meeting from May 18-21, 2019 in Lyon, France. The data...

U.S. Food & Drug Administration Accepts Takeda’s Biologics License Application for a Subcutaneous Formulation... -Thursday 9 May 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for a subcutaneous (SC) formulation of vedolizumab for maintenance therapy in...

Takeda Simplifies Portfolio and Accelerates Deleveraging Through Two Divestitures -Thursday 9 May 2019

Agrees to Sell Xiidra® to Novartis for up to $5.3 billion Company to Also Divest TachoSil® to Ethicon* for approximately $400 million   (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into agreements to...

Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International... -Wednesday 8 May 2019

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited [TSE: 4502 / NYSE: TAK] today announced that it will present a total of five company-sponsored poster presentations, as well as an oral pipeline symposium, at the 15th International Symposium on Myelodysplastic Syndromes taking place in...

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term... -Tuesday 26 March 2019

Impact on patient quality of life quantified including long-term renal and cardiovascular complications Final outcomes of 6 year study into continuous use of rhPTH(1-84) shows improvements in key measurements of mineral homeostasis   (BUSINESS WIRE)-- Takeda Pharmaceutical Company...

Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever... -Saturday 9 March 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha...

European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults... -Tuesday 12 February 2019

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of ADCETRIS (brentuximab vedotin) to include treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin...